Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.45 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897343 | 0.83 | SMN1; SMN2 (0.44) | LMNAALDH1A1BRD4MEN1KMT2A | |
| SCHEMBL8104076 | 0.83 | MRGPRX4 (0.50) | LMNAALDH1A1PTGER1BRD4MEN1 | |
| SCHEMBL17902651 | 0.81 | ALDH1A1 (0.46) | LMNAALDH1A1NPSR1CYP1A2MEN1 | |
| SCHEMBL6855607 | 0.80 | HDAC8 (0.50) | LRRK2LMNAALDH1A1NPSR1MEN1 | |
| SCHEMBL31285651 | 0.80 | PPID (0.43) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL27733225 | 0.79 | BRD4 (0.48) | LRRK2LMNAUSP2CCR5ALDH1A1 | |
| SCHEMBL630140 | 0.79 | MEN1 (0.48) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL31285324 | 0.78 | BRD4 (0.41) | LMNAALDH1A1BRD4MEN1KMT2A | |
| SCHEMBL31277431 | 0.77 | LRRK2 (0.46) | LRRK2LMNAUSP2CCR5ALDH1A1 | |
| SCHEMBL629377 | 0.77 | LRRK2 (0.46) | LRRK2LMNAUSP2CCR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1960377-A1 | l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | Novartis AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067614-A1 | l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | PTPRS, IRS1, PTPMT1 | LRRK2 413/4885LMNA 4819/4885USP2 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.